JP6913026B2 - インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 - Google Patents

インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 Download PDF

Info

Publication number
JP6913026B2
JP6913026B2 JP2017553885A JP2017553885A JP6913026B2 JP 6913026 B2 JP6913026 B2 JP 6913026B2 JP 2017553885 A JP2017553885 A JP 2017553885A JP 2017553885 A JP2017553885 A JP 2017553885A JP 6913026 B2 JP6913026 B2 JP 6913026B2
Authority
JP
Japan
Prior art keywords
ser
isolated
binder
seq
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512157A (ja
JP2018512157A5 (enExample
Inventor
バウワーズ、ピーター
ジョン マックナイト、アンドリュー
ジョン マックナイト、アンドリュー
ジェイ． キング、デイヴィッド
ジェイ． キング、デイヴィッド
ロンデイ、マルコ
Original Assignee
アナプティスバイオ インコーポレイティッド
アナプティスバイオ インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナプティスバイオ インコーポレイティッド, アナプティスバイオ インコーポレイティッド filed Critical アナプティスバイオ インコーポレイティッド
Publication of JP2018512157A publication Critical patent/JP2018512157A/ja
Publication of JP2018512157A5 publication Critical patent/JP2018512157A5/ja
Priority to JP2021069306A priority Critical patent/JP7212098B2/ja
Application granted granted Critical
Publication of JP6913026B2 publication Critical patent/JP6913026B2/ja
Priority to JP2023003385A priority patent/JP7721585B2/ja
Priority to JP2025127775A priority patent/JP2025163120A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017553885A 2015-04-15 2016-04-15 インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 Active JP6913026B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021069306A JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2023003385A JP7721585B2 (ja) 2015-04-15 2023-01-12 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2025127775A JP2025163120A (ja) 2015-04-15 2025-07-30 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147824P 2015-04-15 2015-04-15
US62/147,824 2015-04-15
PCT/US2016/027676 WO2016168542A1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021069306A Division JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Publications (3)

Publication Number Publication Date
JP2018512157A JP2018512157A (ja) 2018-05-17
JP2018512157A5 JP2018512157A5 (enExample) 2019-05-23
JP6913026B2 true JP6913026B2 (ja) 2021-08-04

Family

ID=57126337

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017553885A Active JP6913026B2 (ja) 2015-04-15 2016-04-15 インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体
JP2021069306A Active JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2023003385A Active JP7721585B2 (ja) 2015-04-15 2023-01-12 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2025127775A Pending JP2025163120A (ja) 2015-04-15 2025-07-30 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021069306A Active JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2023003385A Active JP7721585B2 (ja) 2015-04-15 2023-01-12 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2025127775A Pending JP2025163120A (ja) 2015-04-15 2025-07-30 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Country Status (14)

Country Link
US (4) US10526410B2 (enExample)
EP (2) EP4176900A1 (enExample)
JP (4) JP6913026B2 (enExample)
KR (1) KR102666920B1 (enExample)
CN (2) CN107847590B (enExample)
AU (1) AU2016248208B2 (enExample)
CA (1) CA2982555A1 (enExample)
DK (1) DK3283110T3 (enExample)
ES (1) ES2914243T3 (enExample)
MX (2) MX2017013080A (enExample)
PL (1) PL3283110T3 (enExample)
RU (1) RU2745898C2 (enExample)
SG (1) SG11201708061TA (enExample)
WO (1) WO2016168542A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67639B1 (sr) 2011-11-16 2026-02-27 Boehringer Ingelheim Int Anti il-36r antitela
RU2745898C2 (ru) * 2015-04-15 2021-04-02 Анаптисбайо, Инк. Антитела, направленные против рецептора интерлейкина 36 (il-36r)
US20180273627A1 (en) * 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP3400962A1 (en) * 2017-05-09 2018-11-14 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
IL280013B2 (en) 2018-07-16 2026-05-01 Regeneron Pharmaceuticals Inc Anti-IL36R antibodies
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
CN110818796B (zh) * 2018-08-09 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
US11884719B2 (en) * 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
TW202037604A (zh) * 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
EA202192405A1 (ru) 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
JP7802651B2 (ja) 2019-08-07 2026-01-20 アクアラン セラピューティクス コーポレーション 抗ｎａｍｐｔ抗体及びその用途
JP7811772B2 (ja) * 2019-12-05 2026-02-06 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
JP2023536851A (ja) * 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
MX2023010289A (es) * 2021-03-04 2023-09-11 Boehringer Ingelheim Int Uso de anticuerpos anti-il-36r en el tratamiento de la psoriasis pustulosa generalizada.
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
AU2022274319A1 (en) * 2021-05-12 2024-01-04 Anaptysbio, Inc. Antibody composition
EP4370550A1 (en) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2001057219A2 (en) 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
CA2662549C (en) 2006-09-08 2014-10-28 Amgen Inc. Il-1 family variants
NZ579010A (en) 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
RS67639B1 (sr) * 2011-11-16 2026-02-27 Boehringer Ingelheim Int Anti il-36r antitela
EP2797952B1 (en) * 2011-12-28 2019-02-27 ImmunoQure AG Method of providing monoclonal auto-antibodies with desired specificity
US9409977B2 (en) 2013-03-12 2016-08-09 Decimmune Therapeutics, Inc. Humanized, anti-N2 antibodies
RU2745898C2 (ru) * 2015-04-15 2021-04-02 Анаптисбайо, Инк. Антитела, направленные против рецептора интерлейкина 36 (il-36r)
US20180273627A1 (en) 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
IL280013B2 (en) 2018-07-16 2026-05-01 Regeneron Pharmaceuticals Inc Anti-IL36R antibodies
US11884719B2 (en) 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
EA202192405A1 (ru) 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
US20220233710A1 (en) 2019-05-20 2022-07-28 Nantong Yichen Biopharma. Co. Ltd. Bispecific molecule and preparation and use thereof

Also Published As

Publication number Publication date
KR102666920B1 (ko) 2024-05-20
DK3283110T3 (da) 2022-05-23
PL3283110T3 (pl) 2022-06-27
JP2018512157A (ja) 2018-05-17
HK1252009A1 (zh) 2019-05-10
ES2914243T3 (es) 2022-06-08
MX2017013080A (es) 2018-02-09
NZ736535A (en) 2024-08-30
US20200087408A1 (en) 2020-03-19
RU2745898C2 (ru) 2021-04-02
CA2982555A1 (en) 2016-10-20
CN115925932A (zh) 2023-04-07
US20210388095A1 (en) 2021-12-16
BR112017022086A2 (pt) 2018-07-03
AU2016248208B2 (en) 2022-03-24
JP7212098B2 (ja) 2023-01-24
MX2023001791A (es) 2023-03-10
EP3283110B1 (en) 2022-04-20
US12391761B2 (en) 2025-08-19
JP2025163120A (ja) 2025-10-28
AU2016248208A1 (en) 2017-11-09
US20180094065A1 (en) 2018-04-05
EP4176900A1 (en) 2023-05-10
CN107847590B (zh) 2022-07-26
CN107847590A (zh) 2018-03-27
JP2021118710A (ja) 2021-08-12
US20260022181A1 (en) 2026-01-22
KR20180002687A (ko) 2018-01-08
EP3283110A1 (en) 2018-02-21
US10526410B2 (en) 2020-01-07
WO2016168542A1 (en) 2016-10-20
RU2017139481A3 (enExample) 2019-09-19
JP2023040236A (ja) 2023-03-22
EP3283110A4 (en) 2019-02-27
RU2017139481A (ru) 2019-05-15
SG11201708061TA (en) 2017-10-30
JP7721585B2 (ja) 2025-08-12
US11130814B2 (en) 2021-09-28
HK1250941A1 (en) 2019-01-18

Similar Documents

Publication Publication Date Title
JP7721585B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
US20240294631A1 (en) Antibodies directed against interleukin-33 (il-33)
JP2023536851A (ja) 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
HK40086847A (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1250941B (en) Antibodies directed against interleukin 36 receptor (il-36r)
BR112017022086B1 (pt) Anticorpo isolado de receptor de interleucina-36 ou fragmento de ligação ao antígeno do mesmo, composição seus usos
HK1252009B (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1231082B (en) Antibodies directed against interleukin-33 (il-33)
HK1231082A1 (en) Antibodies directed against interleukin-33 (il-33)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171122

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210415

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210415

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210422

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210709

R150 Certificate of patent or registration of utility model

Ref document number: 6913026

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250